Rapid Detection and identification of Synthetic Phosphodiesterase Type-5 Inhibitors in Counterfeit and Adulterated Products using the Atmospheric Solids Analysis Probe

Planta Medica ◽  
2011 ◽  
Vol 77 (05) ◽  
Author(s):  
M Twohig ◽  
G Fujimoto ◽  
N Ellor ◽  
D Shave ◽  
K Yu
Keyword(s):  
Rapid Detection ◽  
Phosphodiesterase Type 5 Inhibitors ◽  
Detection And Identification ◽  
Phosphodiesterase Type ◽  
Solids Analysis

Identification of hepatitis a virus in cell cultures by solid phase immune electron microscopy

1986 ◽  
Vol 44 ◽  
pp. 238-239
Author(s):  
C.D. Humphrey ◽  
T.L. Cromeans ◽  
E.H. Cook ◽  
D.W. Bradley
Keyword(s):  
Electron Microscopy ◽  
Liquid Phase ◽  
Cell Cultures ◽  
Rapid Detection ◽  
Hepatitis A ◽  
Hepatitis A Virus ◽  
Solid Phase ◽  
Immune Electron Microscopy ◽  
Detection And Identification

There is a variety of methods available for the rapid detection and identification of viruses by electron microscopy as described in several reviews. The predominant techniques are classified as direct electron microscopy (DEM), immune electron microscopy (IEM), liquid phase immune electron microscopy (LPIEM) and solid phase immune electron microscopy (SPIEM). Each technique has inherent strengths and weaknesses. However, in recent years, the most progress for identifying viruses has been realized by the utilization of SPIEM.

Repurposing cilostazol for Raynaud's phenomenon

2020 ◽  
Vol 27 ◽  
Author(s):  
Nehme El-Hachem ◽  
Manal M. Fardoun ◽  
Hasan Slika ◽  
Elias Baydoun ◽  
Ali H. Eid
Keyword(s):  
Color Change ◽  
Angiotensin Receptor Blockers ◽  
Raynaud’S Phenomenon ◽  
Blood Perfusion ◽  
Raynaud's Phenomenon ◽  
Channel Blockers ◽  
Phosphodiesterase Type 5 Inhibitors ◽  
Receptor Blockers ◽  
Phosphodiesterase Type ◽  
Food And Drugs Administration

: Raynaud's Phenomenon (RP) results from exaggerated cold-induced vasoconstriction. RP patients suffer from vasospastic attacks and compromised digital blood perfusion leading to triple color change at the level the fingers. Severe RP may cause ulcers and threaten tissue viability. Many drugs have been used to alleviate the symptoms of RP. These include calcium-channel blockers, cGMP-specific phosphodiesterase type 5 inhibitors, prostacyclin analogs, and angiotensin receptor blockers. Despite their variety, these drugs do not treat RP but rather alleviate its symptoms. To date, no drug for RP has been yet approved by U.S Food and Drugs Administration. Cilostazol is a selective inhibitor of phosphodiesteraseIII, originally prescribed to treat intermittent claudication. Owing to its antiplatelet and vasodilating properties, cilostazol is being repurposed as a potential drug for RP. This review focuses on the different lines of action of action of cilostazol serving to enhance blood perfusion in RP patients.

Sign in / Sign up

Export Citation Format

Share Document